Modulation of immunity and inflammation by the Mineralocorticoid receptor and Aldosterone

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Munoz Durango N ^a   Vecchiola, A ^a   Gonzalez Gomez, L M ^a   Simon, F ^a   Riedel, C A ^a   Fardella, C E ^a   Kalergis, A M ^a,b  

^a Pontificia Universidad Católica de Chile   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOSTEROID; MINERALOCORTICOID RECEPTOR; IMMUNOLOGIC FACTOR;

DRUG ANTAGONISM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PATHOLOGY; PRIMARY HYPERALDOSTERONISM; REVIEW; ADRENAL CORTEX; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY;

ADRENAL CORTEX; ALDOSTERONE; ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION; MODELS, IMMUNOLOGICAL; RECEPTORS, MINERALOCORTICOID;

EID: 84942280047     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/652738     Document Type: Review

References (147)

1. S. A. Simpson, J. F. Tait, A. Wettstein, R. Neher, J. Von Euw, and T. Reichstein, "Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism, " Experientia, vol. 9, no. 9, pp. 333-335, 1953.
2. D. Marver and J. P. Kokko, "Renal target sites and the mechanism of action of aldosterone, " Mineral and Electrolyte Metabolism, vol. 9, no. 1, pp. 1-18, 1983.
3. I. Z. Jaffe and M. E. Mendelsohn, "Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells, " Circulation Research, vol. 96, no. 6, pp. 643-650, 2005.
4. A. Nray-Fejes-Tth and G. Fejes-Tth, "The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel, " Kidney International, vol. 57, no. 4, pp. 1290-1294, 2000.
5. A. Derfoul, N. M. Robertson, J. B. Lingrel, D. J. Hall, and G. Litwack, "Regulation of the human Na/K-ATPase beta1 gene promoter by mineralocorticoid and glucocorticoid receptors, " The Journal of Biological Chemistry, vol. 273, no. 33, pp. 20702-20711, 1998.
6. W. Sutanto and E. R. de Kloet, "Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects, " Medicinal Research Reviews, vol. 11, no. 6, pp. 617-639, 1991.
7. V. Robert, J.-S. Silvestre, D. Charlemagne et al. , "Biological determinants of aldosterone-induced cardiac fibrosis in rats, " Hypertension, vol. 26, no. 61, pp. 971-978, 1995.
8. C. G. Brilla, G. Zhou, L. Matsubara, andK. T. Weber, "Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone, " Journal of Molecular and Cellular Cardiology, vol. 26, no. 7, pp. 809-820, 1994.
9. V. Robert, N. van Thiem, S. L. Cheav, C. Mouas, B. Swynghedauw, andC. Delcayre, "Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension, " Hypertension, vol. 24, no. 1, pp. 30-36, 1994.
10. M. A. Weber, R. E. Purdy, and J. I. M. Drayer, "Interactions of mineralocorticoids and pressor agents in vascular smooth muscle, " Hypertension, vol. 5, no. 2, part 2, pp. I41-I46, 1983.
11. M. Zhao, F. Valamanesh, I. Celerier et al. , "The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion andwater channels inMller glial cells, "TheFASEB Journal, vol. 24, no. 9, pp. 3405-3415, 2010.
12. E. Bousquet, M. Zhao, A. Ly et al. , "The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis, " PLoS ONE, vol. 7, no. 11, Article ID e49036, 2012.
13. M. Caprio, B. Feve, A. Clas, S. Viengchareun, M. Lombes, and M.-C. Zennaro, "Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis, " The FASEB Journal, vol. 21, no. 9, pp. 2185-2194, 2007.
14. M. Boscaro, G. Giacchetti, and V. Ronconi, "Visceral adipose tissue: emerging role of gluco-and mineralocorticoid hormones in the setting of cardiometabolic alterations, " Annals of the New York Academy of Sciences, vol. 1264, no. 1, pp. 87-102, 2012.
15. S. Berger, D. P. Wolfer, O. Selbach et al. , "Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 1, pp. 195-200, 2006.
16. K. Hinkelmann, K. Wingenfeld, L. K. Kuehl et al. , "Stimulation of the mineralocorticoid receptor improves memory in young and elderly healthy individuals, " Neurobiology of Aging, vol. 36, no. 2, pp. 919-924, 2015.
17. A. A. Herrada, C. Campino, C. A. Amador, L. F. Michea, C. E. Fardella, and A. M. Kalergis, "Aldosterone as a modulator of immunity: implications in the organ damage, " Journal of Hypertension, vol. 29, no. 9, pp. 1684-1692, 2011.
18. N. Munoz-Durango, M. F. Barake, N. A. Letelier, C. Campino, C. E. Fardella, and A. M. Kalergis, "Immune systemalterations by aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage, " Current Molecular Medicine, vol. 13, no. 6, pp. 1035-1046, 2013.
19. S. Grafte-Faure, C. Leveque, M. Vasse, C. Soria, V. Norris, and J.-P. Vannier, "Effects of glucocorticoids and mineralocorticoids on proliferation and maturation of human peripheral blood stem cells, " American Journal of Hematology, vol. 62, no. 2, pp. 65-73, 1999.
20. P. Rossignol, J. Mnard, R. Fay, F. Gustafsson, B. Pitt, and F. Zannad, "Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy, " Journal of the American College of Cardiology, vol. 58, no. 19, pp. 1958-1966, 2011.
21. R. Rocha, A. E. Rudolph, G. E. Frierdich et al. , "Aldosterone induces a vascular inflammatory phenotype in the rat heart, " American Journal of Physiology: Heart and Circulatory Physiology, vol. 283, no. 5, pp. H1802-H1810, 2002.
22. A. J. Rickard, J. W. Funder, J. Morgan, P. J. Fuller, and M. J. Young, "Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?" Endocrinology, vol. 148, no. 10, pp. 4829-4835, 2007.
23. A. A. Herrada, F. J. Contreras, N. P. Marini et al. , "Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity, " The Journal of Immunology, vol. 184, no. 1, pp. 191-202, 2010.
24. C. De Ciuceis, F. Amiri, P. Brassard, D. H. Endemann, R. M. Touyz, and E. L. Schiffrin, "Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2106-2113, 2005.
25. M. G. Usher, S. Z. Duan, C. Y. Ivaschenko et al. , "Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice, " Journal of Clinical Investigation, vol. 120, no. 9, pp. 3350-3364, 2010.
26. A. J. Rickard, J. Morgan, G. Tesch, J. W. Funder, P. J. Fuller, and M. J. Young, "Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/saltinduced cardiac fibrosis and increased blood pressure, " Hypertension, vol. 54, no. 3, pp. 537-543, 2009.
27. A. Sica and A. Mantovani, "Macrophage plasticity and polarization: in vivo veritas, " The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787-795, 2012.
28. R. Stumpo, M. Kauer, S. Martin, and H. Kolb, "IL-10 induces gene expression in macrophages: partial overlap with IL-5 but not with IL-4 induced genes, " Cytokine, vol. 24, no. 1-2, pp. 46-56, 2003.
29. A. Gratchev, J. Kzhyshkowska, S. Kannookadan et al. , "Activation of a TGF-β-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-β receptor II, " Journal of Immunology, vol. 180, no. 10, pp. 6553-6565, 2008.
30. C. A. Amador, V. Barrientos, J. Pena et al. , "Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes, " Hypertension, vol. 63, no. 4, pp. 797-803, 2014.
31. I. Campbell, "Adrenocortical hormones, "Anaesthesia and Intensive Care Medicine, vol. 12, no. 10, pp. 461-464, 2011.
32. S. Viengchareun, D. Le Menuet, L. Martinerie, M. Munier, L. Pascual-Le Tallec, and M. Lombes, "The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology, " Nuclear Receptor Signaling, vol. 5, article e012, 2007.
33. J. L. Arriza, C. Weinberger, G. Cerelli et al. , "Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor, " Science, vol. 237, no. 4812, pp. 268-275, 1987.
34. J. P. Tuckermann, A. Kleiman, K. G. McPherson, and H. M. Reichardt, "Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis, " Critical Reviews in Clinical Laboratory Sciences, vol. 42, no. 1, pp. 71-104, 2005.
35. B. R. Walker, "Cortisol-cause and cure for metabolic syndrome?" Diabetic Medicine, vol. 23, no. 12, pp. 1281-1288, 2006.
36. W. Miller and G. P. Chrousos, Endochrinology and Metabolism, McGraw-Hill, New York, NY, USA, 4th edition, 2001.
37. S. A. Amero, R. H. Kretsinger, N. D. Moncrief, K. R. Yamamoto, and W. R. Pearson, "The origin of nuclear receptor proteins: a single precursor distinct from other transcription factors, " Molecular Endocrinology, vol. 6, no. 1, pp. 3-7, 1992.
38. F. Payvar, D. DeFranco, G. L. Firestone et al. , "Sequence-specific binding of glucocorticoid receptor toMTV DNA at sites within and upstreamof the transcribed region, " Cell, vol. 35, no. 2, part 1, pp. 381-392, 1983.
39. V. L. Chandler, B. A. Maler, and K. R. Yamamoto, DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo, Cell, vol. 33, no. 2, pp. 489499, 1983.
40. P. J. Fuller, S. S. Lim-Tio, and F. E. Brennan, "Specificity in mineralocorticoid versus glucocorticoid action, " Kidney International, vol. 57, no. 4, pp. 1256-1264, 2000.
41. D. Pearce and K. R. Yamamoto, "Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element, " Science, vol. 259, no. 5098, pp. 1161-1165, 1993.
42. U. Strhle, G. Klock, and G. Schutz, "A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression, " Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 22, pp. 7871-7875, 1987.
43. W. Liu, J. Wang, N. K. Sauter, and D. Pearce, "Steroid receptor heterodimerization demonstrated in vitro and in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 26, pp. 12480-12484, 1995.
44. M. Lombes, N. Binart, M.-E. Oblin, V. Joulin, and E. E. Baulieu, "Characterization of the interaction of the human mineralocorticosteroid receptor with hormone response elements, " Biochemical Journal, vol. 292, no. 2, pp. 577-583, 1993.
45. J. Yang andM. J. Young, "Themineralocorticoid receptor and its coregulators, " Journal ofMolecular Endocrinology, vol. 43, no. 2, pp. 53-64, 2009.
46. M. Lombes, S. Kenouch, A. Souque, N. Farman, and M.-E. Rafestin-Oblin, "The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 β-hydroxysteroid dehydrogenase, " Endocrinology, vol. 135, no. 3, pp. 834-840, 1994.
47. N. Farman and B. Bocchi, "Mineralocorticoid selectivity: molecular and cellular aspects, " Kidney International, vol. 57, no. 4, pp. 1364-1369, 2000.
48. J. W. Funder, P. T. Pearce, R. Smith, and A. I. Smith, "Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated, " Science, vol. 242, no. 4878, pp. 583-585, 1988.
49. M. Nishi, M. Tanaka, K.-I. Matsuda, M. Sunaguchi, and M. Kawata, "Visualization of glucocorticoid receptor and mineralocorticoild receptor interactions in living cells with GFPbased fluorescence resonance energy transfer, " The Journal of Neuroscience, vol. 24, no. 21, pp. 4918-4927, 2004.
50. T. Trapp, R. Rupprecht, M. Castren, J. M. H. M. Reul, and F. Holsboer, "Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS, " Neuron, vol. 13, no. 6, pp. 1457-1462, 1994.
51. M. Tsugita, Y. Iwasaki, M. Nishiyama et al. , "Glucocorticoid receptor plays an indispensable role in mineralocorticoid receptor-dependent transcription in GR-deficient BE(2)C and T84 cells in vitro, " Molecular and Cellular Endocrinology, vol. 302, no. 1, pp. 18-25, 2009.
52. T. Trapp and F. Holsboer, "Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action, " Trends in Pharmacological Sciences, vol. 17, no. 4, pp. 145-149, 1996.
53. N. Faresse, "Post-translational modifications of the mineralocorticoid receptor: how to dress the receptor according to the circumstances?" Journal of Steroid Biochemistry and Molecular Biology, vol. 143, pp. 334-342, 2014.
54. C. Le Mollic, A. Ouvrard-Pascaud, C. Capurro et al. , "Early nongenomic events in aldosterone action in renal collecting duct cells: PKCα activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response, " Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1145-1160, 2004.
55. R. F. Walther, E. Atlas, A. Carrigan et al. , "A serine/threoninerich motif is one of three nuclear localization signals that determine unidirectional transport of the mineralocorticoid receptor to the nucleus, " The Journal of Biological Chemistry, vol. 280, no. 17, pp. 17549-17561, 2005.
56. S. Shibata, J. Rinehart, J. Zhang et al. , "Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia, " Cell Metabolism, vol. 18, no. 5, pp. 660-671, 2013.
57. E. Falkenstein, M. Christ, M. Feuring, and M. Wehling, "Specific nongenomic actions of aldosterone, " Kidney International, vol. 57, no. 4, pp. 1390-1394, 2000.
58. M. Gekle and C. Grossmann, "Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?" Pflugers Archiv European Journal of Physiology, vol. 458, no. 2, pp. 231-246, 2009.
59. M. Lombes, N. Farman, J. P. Bonvalet, and M.-C. Zennaro, "Identification and role of aldosterone receptors in the cardiovascular system, " Annales dEndocrinologie, vol. 61, no. 1, pp. 41-46, 2000.
60. K. Yokota, H. Shibata, S. Kobayashi et al. , "Proteasomemediated mineralocorticoid receptor degradation attenuates transcriptional response to aldosterone, " Endocrine Research, vol. 30, no. 4, pp. 611-616, 2004.
61. G. Piwien-Pilipuk and M. D. Galigniana, "Oxidative stress induced by L-buthionine-(S, R)-sulfoximine, a selective inhibitor of glutathione metabolism, abrogates mouse kidney mineralocorticoid receptor function, " Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1495, no. 3, pp. 263-280, 2000.
62. A. Souque, J. Fagart, B. Couette, and M.-E. Rafestin-Oblin, "Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor, "TheJournal of Steroid Biochemistry and Molecular Biology, vol. 57, no. 5-6, pp. 315-321, 1996.
63. P. Libby, "Inflammation and cardiovascular disease mechanisms, " The American Journal of Clinical Nutrition, vol. 83, pp. 456S-460S, 2006.
64. C. U. Chae, R. T. Lee, N. Rifai, andP. M. Ridker, "Blood pressure and inflammation in apparently healthy men, " Hypertension, vol. 38, no. 3, pp. 399-403, 2001.
65. E. L. Schiffrin, "Inflammation, immunity and development of essential hypertension, " Journal of Hypertension, vol. 32, no. 2, pp. 228-229, 2014.
66. B. Pitt, F. Zannad, W. J. Remme et al. , "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, " The New England Journal of Medicine, vol. 341, no. 10, pp. 709-717, 1999.
67. B. Pitt, W. Remme, F. Zannad et al. , "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, " The New England Journal of Medicine, vol. 348, no. 14, pp. 1309-1321, 2003.
68. V. Godfrey, C. A. J. Farquharson, J. E. Macdonald, K.-M. Yee, and A. D. Struthers, "Effect of spironolactone on C-reactive protein levels in patients with heart disease, " International Journal of Cardiology, vol. 117, no. 2, pp. 282-284, 2007.
69. K. Bendtzen, P. R. Hansen, K. Rieneck et al. , "Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma and has potential in the treatment of arthritis, " Clinical and Experimental Immunology, vol. 134, no. 1, pp. 151-158, 2003.
70. C. S. Haas, C. J. Creighton, X. Pi et al. , "Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines fromdiseasediscordant monozygotic twins, " Arthritis and Rheumatism, vol. 54, no. 7, pp. 2047-2060, 2006.
71. M. Schmidt, C. Weidler, H. Naumann, S. Anders, J. Schlmerich, and R. H. Straub, "Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system?" Arthritis and Rheumatism, vol. 52, no. 6, pp. 1711-1720, 2005.
72. S. E. Nielsen, F. Persson, E. Frandsen et al. , "Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebocontrolled crossover study, " DiabeticMedicine, vol. 29, no. 8, pp. e184-e190, 2012.
73. S. E. Nielsen, K. J. Schjoedt, K. Rossing et al. , "Levels of NTproBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease, " Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 2, pp. 161-166, 2013.
74. C. G. Brilla and K. T. Weber, "Mineralocorticoid excess, dietary sodium, and myocardial fibrosis, " Journal of Laboratory and Clinical Medicine, vol. 120, no. 6, pp. 893-901, 1992.
75. T. Hattori, T. Murase, E. Iwase et al. , "Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism, " Nagoya Journal of Medical Science, vol. 75, no. 1-2, pp. 81-92, 2013.
76. M. J. Young, J. Morgan, K. Brolin, P. J. Fuller, and J. W. Funder, "Activation of mineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats, " Endocrinology, vol. 151, no. 6, pp. 2622-2628, 2010.
77. P. Kolkhof and S. A. Borden, "Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics, " Molecular and Cellular Endocrinology, vol. 350, no. 2, pp. 310-317, 2012.
78. P. R. Hansen, K. Rieneck, and K. Bendtzen, "Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells, " Immunology Letters, vol. 91, no. 2-3, pp. 87-91, 2004.
79. S. U. S. Sder, M. Mikkelsen, K. Rieneck, C. J. Hedegaard, and K. Bendtzen, "Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction, " British Journal of Pharmacology, vol. 148, no. 1, pp. 46-53, 2006.
80. K. Labuzek, S. Liber, L. Buldak, G. Machnik, J. Liber, and B. Okopie, "Eplerenone promotes alternative activation in human monocyte-derived macrophages, " Pharmacological Reports, vol. 65, no. 1, pp. 226-234, 2013.
81. H.-Y. Lim, N. Mller, M. J. Herold, J. Van Den Brandt, and H. M. Reichardt, "Glucocorticoids exert opposing effects on macrophage function dependent on their concentration, " Immunology, vol. 122, no. 1, pp. 47-53, 2007.
82. C. N. Lumeng and A. R. Saltiel, "Inflammatory links between obesity and metabolic disease, "The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2111-2117, 2011.
83. C. Guo, V. Ricchiuti, B. Q. Lian et al. , "Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines, " Circulation, vol. 117, no. 17, pp. 2253-2261, 2008.
84. M. Caprio, A. Antelmi, G. Chetrite et al. , "Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome, " Endocrinology, vol. 152, no. 1, pp. 113-125, 2011.
85. D. Kraus, J. Jger, B. Meier, M. Fasshauer, and J. Klein, "Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes, " Hormone and Metabolic Research, vol. 37, no. 7, pp. 455-459, 2005.
86. S. Thatcher, F. Yiannikouris, M. Gupte, and L. Cassis, "The adipose renin-angiotensin system: role in cardiovascular disease, " Molecular and Cellular Endocrinology, vol. 302, no. 2, pp. 111-117, 2009.
87. S. Schinner, H. S. Willenberg, D. Krause et al. , "Adipocytederived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through theWnt-signaling pathway, " International Journal of Obesity, vol. 31, no. 5, pp. 864-870, 2007.
88. M. Nagase, S. Yoshida, S. Shibata et al. , "Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors, " Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3438-3446, 2006.
89. V. Lamounier-Zepter, M. Ehrhart-Bornstein, and S. R. Bornstein, "Mineralocortoid-stimulating activity of adipose tissue, " Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 19, no. 4, pp. 567-575, 2005.
90. M. Ehrhart-Bornstein, K. Arakelyan, A. W. Krug, W. A. Scherbaum, and S. R. Bornstein, "Fat cells may be the obesityhypertension link: human adipogenic factors stimulate aldosterone secretion fromadrenocortical cells, " Endocrine Research, vol. 30, no. 4, pp. 865-870, 2004.
91. A. M. Briones, A. N. D. Cat, G. E. Callera et al. , "Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction, " Hypertension, vol. 59, no. 5, pp. 1069-1078, 2012.
92. M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven et al. , "Human adipocytes secrete mineralocorticoid-releasing factors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 14211-14216, 2003.
93. G. P. Rossi, D. Sticchi, L. Giuliani et al. , "Adiponectin receptor expression in the human adrenal cortex and aldosteroneproducing adenomas, " International Journal of Molecular Medicine, vol. 17, no. 6, pp. 975-980, 2006.
94. R. Rocha, P. N. Chander, K. Khanna, A. Zuckerman, and C. T. Stier Jr. , "Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats, " Hypertension, vol. 31, no. 1, pp. 451-458, 1998.
95. E. Y. M. Lam, J. W. Funder, D. J. Nikolic-Paterson, P. J. Fuller, and M. J. Young, "Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/ salt rats, " Endocrinology, vol. 147, no. 7, pp. 3623-3629, 2006.
96. J. Iwanami, M. Mogi, S. Okamoto et al. , "Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusionmodel, " European Journal of Pharmacology, vol. 566, no. 1-3, pp. 153-159, 2007.
97. R. A. Frieler, H. Meng, S. Z. Duan et al. , "Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia, " Stroke, vol. 42, no. 1, pp. 179-185, 2011.
98. E. Fischer, C. Adolf, A. Pallauf et al. , "Aldosterone excess impairs first phase insulin secretion in primary aldosteronism, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. 2513-2520, 2013.
99. J. W. Conn, "Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome, " Journal of Laboratory and Clinical Medicine, vol. 45, no. 1, pp. 3-17, 1955.
100. A. M. Sawka, J. Young, G. B. Thompson et al. , "Primary aldosteronism: factors associated with normalization of blood pressure after surgery, " Annals of Internal Medicine, vol. 135, no. 4, pp. 258-261, 2001.
101. M. H. Weinberger, C. E. Grim, J. W. Hollifield et al. , "Primary aldosteronism: diagnosis, localization, and treatment, " Annals of Internal Medicine, vol. 90, no. 3, pp. 386-395, 1979.
102. C. E. Fardella, L. Mosso, C. Gmez-Snchez et al. , "Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology, " Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 5, pp. 1863-1867, 2000.
103. L. Mosso, C. Carvajal, A. Gonzlez et al. , "Primary aldosteronism and hypertensive disease, " Hypertension, vol. 42, no. 2, pp. 161-165, 2003.
104. C. B. Stehr, R. Mellado, M. P. Ocaranza et al. , "Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients, " Journal of Hypertension, vol. 28, no. 10, pp. 2120-2126, 2010.
105. P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad, "Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism, " Journal of the American College of Cardiology, vol. 45, no. 8, pp. 1243-1248, 2005.
106. J.-M. Halimi and A. Mimran, "Albuminuria in untreated patients with primary aldosteronism or essential hypertension, " Journal of Hypertension, vol. 13, no. 12, pp. 1801-1802, 1995.
107. W. F. Young, "Primary aldosteronism: renaissance of a syndrome, " Clinical Endocrinology, vol. 66, no. 5, pp. 607-618, 2007.
108. G. P. Rossi, V. Di Bello, C. Ganzaroli et al. , "Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism, " Hypertension, vol. 40, no. 1, pp. 23-27, 2002.
109. G. P. Rossi, A. Sacchetto, E. Pavan et al. , "Remodeling of the left ventricle in primary aldosteronism due to Conns adenoma, " Circulation, vol. 95, no. 6, pp. 1471-1478, 1997.
110. L. C. Martins, V. N. Figueiredo, T. Quinaglia et al. , "Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness, " Journal of Human Hypertension, vol. 25, no. 9, pp. 532-538, 2011.
111. R. Rocha, P. N. Chander, A. Zuckerman, and C. T. Stier, "Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats, " Hypertension, vol. 33, no. 1, pp. 232-237, 1999.
112. L. D. Dworkin, T. H. Hostetter, H. G. Rennke, and B. M. Brenner, "Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension, " The Journal of Clinical Investigation, vol. 73, no. 5, pp. 1448-1460, 1984.
113. G. P. Rossi, G. Bernini, G. Desideri et al. , "Renal damage in primary aldosteronism: results of the PAPY study, " Hypertension, vol. 48, no. 2, pp. 232-238, 2006.
114. A. Nishiyama, L. Yao, Y. Nagai et al. , "Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats, " Hypertension, vol. 43, no. 4, pp. 841-848, 2004.
115. E. Kotlyar, J. A. Vita, M. R. Winter et al. , "The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure, " Journal of Cardiac Failure, vol. 12, no. 2, pp. 122-127, 2006.
116. N. Queisser, K. Happ, S. Link et al. , "Aldosterone induces fibrosis, oxidative stress andDNA damage in livers of male rats independent of blood pressure changes, " Toxicology and Applied Pharmacology, vol. 280, no. 3, pp. 399-407, 2014.
117. E. C. Viel, K. Benkirane, D. Javeshghani, R. M. Touyz, and E. L. Schiffrin, "Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats, " The American Journal of Physiology: Heart and Circulatory Physiology, vol. 295, no. 1, pp. H281-H288, 2008.
118. N. Schupp, P. Kolkhof, N. Queisser et al. , "Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats, " The FASEB Journal, vol. 25, no. 3, pp. 968-978, 2011.
119. Z.-H. Zhang, Y. Yu, Y.-M. Kang, S.-G. Wei, and R. B. Felder, "Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 2, pp. H1067-H1074, 2008.
120. A. Zhang, Z. Jia, N. Wang, T. J. Tidwell, and T. Yang, "Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice, " Kidney International, vol. 80, no. 1, pp. 51-60, 2011.
121. N. Queisser, P. I. Oteiza, H. Stopper, R. G. Oli, and N. Schupp, "Aldosterone induces oxidative stress, oxidative DNA damage andNF-κB-activation in kidney tubule cells, "Molecular Carcinogenesis, vol. 50, no. 2, pp. 123-135, 2011.
122. N. J. Brown, "Aldosterone and vascular inflammation, " Hypertension, vol. 51, no. 2, pp. 161-167, 2008.
123. K. T. Weber and C. G. Brilla, "Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system, " Circulation, vol. 83, no. 6, pp. 1849-1865, 1991.
124. A. E. Rudolph, R. Rocha, and E. G. McMahon, "Aldosterone target organ protection by eplerenone, " Molecular and Cellular Endocrinology, vol. 217, no. 1-2, pp. 229-238, 2004.
125. P. J. Fuller andM. J. Young, "Mechanisms ofmineralocorticoid action, " Hypertension, vol. 46, no. 6, pp. 1227-1235, 2005.
126. K. T. Weber, C. G. Brilla, S. E. Campbell, E. Guarda, G. Zhou, and K. Sriram, "Myocardial fibrosis: role of angiotensin II and aldosterone, " Basic Research in Cardiology, vol. 88, supplement 1, pp. 107-124, 1993.
127. R. Krysiak and B. Okopien, "The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma, " Hypertension Research, vol. 35, no. 1, pp. 123-125, 2012.
128. J. Irita, T. Okura, S. Manabe et al. , "Plasmaosteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension, " American Journal of Hypertension, vol. 19, no. 3, pp. 293-297, 2006.
129. C. A. Carvajal, A. A. Herrada, C. R. Castillo et al. , "Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha, " Journal of Endocrinological Investigation, vol. 32, no. 9, pp. 759-765, 2009.
130. G. Rossitto, G. Regolisti, E. Rossi et al. , "Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma, " Hypertension, vol. 61, no. 2, pp. 526-533, 2013.
131. D. C. Kem, H. Li, X. Yu, A. Benbrook, M. V. Cicala, and F. Mantero, "AT1R activating autoantibodies occur in both aldosterone producing adenoma and idiopathic adrenal hyperplasia subgroups in primary aldosteronism, " in Adrenal Tumors: Cushings, Conns, Pheochromocytoma, SUN-0811-SUN-0811, Endocrine Society, 2014.
132. H. Oberleithner, T. Ludwig, C. Riethmuller et al. , "Human endothelium: target for aldosterone, " Hypertension, vol. 43, no. 5, pp. 952-956, 2004.
133. N. Golestaneh, C. Klein, F. Valamanesh, G. Suarez, M. K. Agarwal, and M. Mirshahi, "Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton, " Biochemical and Biophysical Research Communications, vol. 280, no. 5, pp. 1300-1306, 2001.
134. M. Caprio, B. G. Newfell, A. La Sala et al. , "Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion, " Circulation Research, vol. 102, no. 11, pp. 1359-1367, 2008.
135. N. Yamamoto, H. Yasue, Y. Mizuno et al. , "Aldosterone is produced from ventricles in patients with essential hypertension, " Hypertension, vol. 39, no. 5, pp. 958-962, 2002.
136. Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, andH. Mabuchi, "Cardiac aldosterone production in genetically hypertensive rats, " Hypertension, vol. 36, no. 4, pp. 495-500, 2000.
137. E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E. Gomez-Sanchez, "Origin of aldosterone in the rat heart, " Endocrinology, vol. 145, no. 11, pp. 4796-4802, 2004.
138. P. Ye, C. J. Kenyon, S. M. MacKenzie et al. , "The aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) genes are not expressed in the rat heart, " Endocrinology, vol. 146, no. 12, pp. 5287-5293, 2005.
139. M. A. Hermoso and J. A. Cidlowski, "Putting the brake on inflammatory responses: the role of glucocorticoids, " IUBMB Life, vol. 55, no. 9, pp. 497-504, 2003.
140. N. Dhanasekaran and E. Premkumar Reddy, "Signaling by dual specificity kinases, " Oncogene, vol. 17, no. 11, pp. 1447-1455, 1998.
141. S. Gauer, I. A. Hauser, N. Obermller, Y. Holzmann, H. Geiger, andM. Goppelt-Struebe, "Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells, " Journal of Cellular Biochemistry, vol. 103, no. 2, pp. 615-623, 2008.
142. J. Irita, T. Okura, M. Kurata, K.-I. Miyoshi, T. Fukuoka, and J. Higaki, "Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone, " Hypertension, vol. 51, no. 2, part 2, pp. 507-513, 2008.
143. A. Kiyosue, D. Nagata, M. Myojo et al. , "Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element, " Hypertension Research, vol. 34, no. 12, pp. 1283-1287, 2011.
144. B. Chantong, D. V. Kratschmar, L. G. Nashev, Z. Balazs, and A. Odermatt, "Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells, " Journal of Neuroinflammation, vol. 9, no. 1, article 260, 2012.
145. C. Latouche, S. El Moghrabi, S. Messaoudi et al. , "Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system, " Hypertension, vol. 59, no. 5, pp. 966-972, 2012.
146. J. M. Cheng, K. M. Akkerhuis, O. Meilhac et al. , "Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 5, pp. 1078-1084, 2014.
147. M. Bleich, R. Warth, M. Schmidt-Hieber et al. , "Rescue of the mineralocorticoid receptor knock-out mouse, " Pflugers Archiv, vol. 438, no. 3, pp. 245-254, 1999.